Navigation Links
Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/8/2007

- Conference Call and Webcast on November 9 at 8:00 a.m. PST -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today reported financial results for the three and nine months ended September 30, 2007.

"Halozyme's unique capabilities in navigating the complexities of the extracellular matrix provide a number of exciting opportunities to build shareholder value," said Jonathan Lim, MD, Halozyme's President and CEO. "Building on our track record for accelerated development and commercialization and leveraging the franchises of our partners, we continue to pursue these opportunities by executing our Enable, Improve and Innovate programs. The Enable program focuses on making our partners' drugs better by potentially improving administration, extending product lifecycles, and increasing patients' compliance, and includes HYLENEX recombinant (hyaluronidase human injection) and our Enhanze(TM) Technology for drug delivery. In this regard, we are very pleased that we recently broadened our relationship with Baxter to apply our Enhanze Technology to their GAMMAGARD product. We are also excited about developing our own products through the Improve program, which focuses on co-formulations of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs; and the Innovate program, which focuses on developing new molecular entities targeting the extracellular matrix with some exciting projects underway in oncology and dermatology."

Third Quarter 2007 Highlights

-- The completion of a new agreement with Baxter International Inc. to

a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Research and Markets has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... pulp & paper industry. The report provides ... applications and industry chain structure. The enzyme for pulp ...
(Date:8/27/2014)... Tris Pharma, a specialty pharmaceutical company focused ... it has been selected as an award winner in ... Awards for Excellence competition in the Business Expansion ... judges from SCORE (Counselors to America,s Small Business) and ... at a gala event to be held on October ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 After the ... reason that the next beverage craze is going to ... today that formulators can use Stress Relief energy pattern ... in the making of a beverage, including minerals, herbs ... stress-generated energy, channeling that power into rapid recovery and ...
(Date:8/27/2014)... WriteResult, LLC – a premier provider of ePRO ... when it comes to meeting the needs of a ... their most recent study closeout on-time and with near ... writing platform to collect Patient Reported Outcomes electronically for ... data from a number of assessments including the IBS-Severity ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... for Cancer Research (OICR) announced today it has enhanced ... called the IPDC Fund. The augmented program is designed ... stage technologies. "In the face of declining ... to offer greater support for the most promising Ontario-based ...
... Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today ... 2011 Conference on Tuesday, March 15th at 3.30 PM ... Convention Centre, Milan, Italy.Bio Europe Spring 2011CTI Presentation: Tuesday, ... AM PSTRoom Yellow 2, Milano Convention Centre (MIC) Media ...
... This release is available in German . ... which make them promising candidates for optoelectronic components. However, ... or influence their optic and electronic properties. A team ... at the Technische Universitaet Muenchen and member of the ...
Cached Biology Technology:Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program 2Ultra fast photodetectors out of carbon nanotubes 2
(Date:8/27/2014)... it is related to ability that we already possess. ... melody more easily than learning how to hit a ... the Neural Basis of Cognition (CNBC)a joint program between ... a fundamental constraint in the brain that may explain ... the Aug. 28, 2014, issue of Nature , ...
(Date:8/27/2014)... of Utah biologist agan Sekercioglu, who campaigns to save ... highest science prize, which is similar to the U.S. ... researchers picked for 2014 the top awards by TUBITAK, ... researchers won the Science Award and two including ... to the Science Award but for scientists who are ...
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3University of Utah biologist wins Turkey's top science prize 2
... scientists have received new funding for a research program ... economically feasible. The project is based on the serendipitous ... fish cages in Puerto Rico by the thousands. The ... fascinating habits such as their tendency to crawl in ...
... mussels and oysters are important vehicles for the ... undercooked. Vibrio species, including human pathogens, are particularly ... even after cleaning procedures, thus representing a potential ... are well known to affect the persistence of ...
... during the summer in Alaska waters, is one of the ... in the 1800s has now left us with only a ... different species from right whales seen in the North Atlantic ... areas and ecological parameters critical to the survival of this ...
Cached Biology News:New project aims to make large-scale lobster farms feasible 2New project aims to make large-scale lobster farms feasible 3Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: